WHO ICTRP trial
Double-blind randomized trial comparing efficacy, safety and tolerance between…
NL-OMON39513 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON39513 |
|---|---|
| Public title | Double-blind randomized trial comparing efficacy, safety and tolerance between Levetiracetam monotherapy and Valproic acid monotherapy in children with newly diagnosed epilepsy |
| Scientific title | Double-blind randomized trial comparing efficacy, safety and tolerance between Levetiracetam monotherapy and Valproic acid monotherapy in children with newly diagnosed epilepsy - LEVVPA |
| Primary sponsor | Universitair Medisch Centrum Groningen |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 3 |
| Countries | Netherlands |
| Conditions | epilepsy seizures;10039911;epilepsy;seizures |
| Interventions | One group will receive levetiracetam (LEV) monotherapy 15-60mg/kg/day, the other group valproic acid (VPA) monotherapy 10-40mg/kg/day. Treatment will start with a low dose and can be increased every 2 weeks until the optimal dose is… |
| Registration date | Dec 30, 2013 |
| Target size | 200 |
| Secondary IDs | 2010-018284-42;NL41142.042.12;NTR3784 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: